BCAB Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

SPRZEDAż 137144 min ago

@ $2.35

Wydano: 14 vas. 2024 @ 16:33

Zwrot: 20.43%

Poprzedni sygnał: vas. 12 - 17:14

Poprzedni sygnał: Kupno

Zwrot: -12.31 %

Live Chart Being Loaded With Signals

Commentary (17 geg. 2024 @ 23:00):

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer...

Stats
Dzisiejszy wolumen	570 285
Średni wolumen	642 980
Kapitalizacja rynkowa	136.17M
EPS	$0 ( 2024-05-14 )
Następna data zysków	( $-0.490 ) 2024-08-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.140
ATR14	$0.00800 (0.28%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-30	Sievers Eric	Sell	572	Common Stock
2024-04-30	Smith Scott Andrew	Sell	2 181	Common Stock
2024-03-31	Smith Scott Andrew	Sell	2 181	Common Stock
2024-03-31	Sievers Eric	Sell	572	Common Stock
2024-02-29	Smith Scott Andrew	Sell	2 181	Common Stock

INSIDER POWER
93.68
Last 100 transactions
Buy: 3 003 180 \| Sell: 89 297

Wolumen Korelacja

Długi: -0.09 (neutral)

Krótki: 0.81 (strong)

Signal:(37.396) Same movement expected

BioAtla, Inc. Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

BioAtla, Inc. Korelacja - Waluta/Towar

-0.06
( neutral )

-0.11
( neutral )

0.00
( neutral )

0.24
( neutral )

0.00
( neutral )

0.38
( neutral )

BioAtla, Inc. Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-1.22M (0.00 %)
EPS:	$-2.58

FY	2023
Przychody:	$0
Zysk brutto:	$-1.22M (0.00 %)
EPS:	$-2.58

FY	2022
Przychody:	$0
Zysk brutto:	$-1.20M (0.00 %)
EPS:	$-2.70

FY	2021
Przychody:	$250 000
Zysk brutto:	$250 000 (100.00 %)
EPS:	$0

Financial Reports:

No articles found.

BioAtla, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

BioAtla, Inc.

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.